6575 Stock Overview
SyneuRx International (Taiwan) Corp., a clinical-stage biotech company, develops drugs for the treatment of unmet medical needs in central nervous system disorders in Taiwan.
SyneuRx International (Taiwan) Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||NT$70.20|
|52 Week High||NT$90.00|
|52 Week Low||NT$39.70|
|1 Month Change||-10.00%|
|3 Month Change||19.79%|
|1 Year Change||71.85%|
|3 Year Change||58.64%|
|5 Year Change||-11.94%|
|Change since IPO||-73.10%|
Recent News & Updates
SyneuRx International (Taiwan) (GTSM:6575) Is In A Good Position To Deliver On Growth Plans
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
|6575||TW Pharmaceuticals||TW Market|
Return vs Industry: 6575 exceeded the TW Pharmaceuticals industry which returned 2.9% over the past year.
Return vs Market: 6575 exceeded the TW Market which returned 1.7% over the past year.
|6575 Average Weekly Movement||8.6%|
|Pharmaceuticals Industry Average Movement||5.4%|
|Market Average Movement||4.6%|
|10% most volatile stocks in TW Market||8.3%|
|10% least volatile stocks in TW Market||2.1%|
Stable Share Price: 6575 is more volatile than 90% of TW stocks over the past 3 months, typically moving +/- 9% a week.
Volatility Over Time: 6575's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of TW stocks.
About the Company
|2013||n/a||Guochuan Emil Tsai||https://www.syneurx.com|
SyneuRx International (Taiwan) Corp., a clinical-stage biotech company, develops drugs for the treatment of unmet medical needs in central nervous system disorders in Taiwan. Its pipeline includes Pentarlandir, which is in Phase II clinical trials for COVID-19; Airnecflu that is in Phase I clinical trials for COVID-19; NaBen, which is in Phase III clinical trials for adult schizophrenia, as well as in Phase II clinical trials adolescent schizophrenia; ClozaBen that is in Phase II clinical trials for refractory schizophrenia; NaBen, which is in Phase II clinical trials for early dementia; Tannquilynne that is in Phase II clinical trials for dementia and psychosis; Synapsinae, which is in Phase II clinical trials for early dementia and psychosis; and Synxyrin that is in Phase II clinical trials for early TRD and suicidality. SyneuRx International (Taiwan) Corp. was founded in 2013 and is based in New Taipei City, Taiwan.
SyneuRx International (Taiwan) Fundamentals Summary
|6575 fundamental statistics|
Is 6575 overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|6575 income statement (TTM)|
|Cost of Revenue||NT$0|
Last Reported Earnings
Dec 31, 2021
Next Earnings Date
|Earnings per share (EPS)||-2.61|
|Net Profit Margin||0.00%|
How did 6575 perform over the long term?See historical performance and comparison
Is SyneuRx International (Taiwan) undervalued compared to its fair value and its price relative to the market?
Valuation Score 0/6
Below Fair Value
Significantly Below Fair Value
PE vs Industry
PE vs Market
PB vs Industry
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate 6575's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate 6575's fair value for valuation analysis.
Price To Earnings Ratio
PE vs Industry: 6575 is unprofitable, so we can't compare its PE Ratio to the TW Pharmaceuticals industry average.
PE vs Market: 6575 is unprofitable, so we can't compare its PE Ratio to the TW market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate 6575's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: 6575 is overvalued based on its PB Ratio (19.8x) compared to the TW Pharmaceuticals industry average (2x).
How is SyneuRx International (Taiwan) forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Future Growth Score0/6
Future Growth Score 0/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as SyneuRx International (Taiwan) has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
How has SyneuRx International (Taiwan) performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 6575 is currently unprofitable.
Growing Profit Margin: 6575 is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: 6575 is unprofitable, and losses have increased over the past 5 years at a rate of 2.9% per year.
Accelerating Growth: Unable to compare 6575's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 6575 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-7.6%).
Return on Equity
High ROE: 6575 has a negative Return on Equity (-73.46%), as it is currently unprofitable.
How is SyneuRx International (Taiwan)'s financial position?
Financial Health Score5/6
Financial Health Score 5/6
Short Term Liabilities
Long Term Liabilities
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: 6575's short term assets (NT$448.1M) exceed its short term liabilities (NT$38.3M).
Long Term Liabilities: 6575's short term assets (NT$448.1M) exceed its long term liabilities (NT$24.2M).
Debt to Equity History and Analysis
Debt Level: 6575 is debt free.
Reducing Debt: 6575 had no debt 5 years ago.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: 6575 has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: 6575 has less than a year of cash runway if free cash flow continues to reduce at historical rates of 7.3% each year
What is SyneuRx International (Taiwan) current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Future Dividend Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate 6575's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate 6575's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if 6575's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if 6575's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as 6575 has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Guochuan Emil Tsai
Mr. Guochuan Emil Tsai, MD PhD MAS serves as Chairman and Chief Executive Officer of SyneuRx International (Taiwan) Corp. Guochuan Emil Tsai is an Assistant Professor at Harvard Medical School. Guochuan Em...
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 9.4%.
SyneuRx International (Taiwan) Corp.'s employee growth, exchange listings and data sources
- Name: SyneuRx International (Taiwan) Corp.
- Ticker: 6575
- Exchange: TPEX
- Founded: 2013
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: NT$8.486b
- Shares outstanding: 120.88m
- Website: https://www.syneurx.com
- SyneuRx International (Taiwan) Corp.
- No. 99, Xintai 5th Road
- 20th Floor-10
- New Taipei City
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/05/19 00:00|
|End of Day Share Price||2022/05/19 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.